Imaging and Biological Markers for Prediction and Identification of Glioblastoma Pseudoprogression: a Prospective Study.
In: Stem Cell Week, 2023-11-21, S. 205-205
serialPeriodical
Zugriff:
This document provides information about an upcoming clinical trial for the treatment of glioblastoma, a type of brain tumor. The trial aims to develop and validate imaging markers and biomarkers that can differentiate between pseudoprogression and true tumor progression. Participants will undergo diagnostic procedures such as PET scans and MRIs, as well as standard treatment with radiotherapy and chemotherapy. The trial aims to advance treatment options for future patients, although there are no expected benefits for individual participants. The trial is not yet recruiting and is estimated to be completed by December 2026. [Extracted from the article]
Copyright of Stem Cell Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Imaging and Biological Markers for Prediction and Identification of Glioblastoma Pseudoprogression: a Prospective Study.
|
---|---|
Zeitschrift: | Stem Cell Week, 2023-11-21, S. 205-205 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1537-1360 (print) |
Sonstiges: |
|